{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:41:03Z","timestamp":1760838063119,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS047198"],"award-info":[{"award-number":["NS047198"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bmc.2022.117131","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:41:40Z","timestamp":1671136900000},"page":"117131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein"],"prefix":"10.1016","volume":"78","author":[{"given":"Bidyut","family":"Dinda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banibrata","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horrick","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepthi","family":"Yedlapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Reith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloke K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.117131_b0005","unstructured":"G.F. Wooten, Movement Disorders. Neurologic Principles and Practice, McGraw-Hill, New York, NY, USA, 1997."},{"key":"10.1016\/j.bmc.2022.117131_b0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer's disease: strategies for disease modification","volume":"9","author":"Citron","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2022.117131_b0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2022.117131_b0020","doi-asserted-by":"crossref","unstructured":"Forno, L. S. (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55, 259-272, PMID 8786384.","DOI":"10.1097\/00005072-199603000-00001"},{"key":"10.1016\/j.bmc.2022.117131_b0025","doi-asserted-by":"crossref","unstructured":"Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840, PMID 9278044.","DOI":"10.1038\/42166"},{"key":"10.1016\/j.bmc.2022.117131_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JPD-181471","article-title":"A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein","volume":"9","author":"Merchant","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.bmc.2022.117131_b0035","doi-asserted-by":"crossref","unstructured":"Stefanis, L. (2012) alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2, a009399, PMID 22355802.","DOI":"10.1101\/cshperspect.a009399"},{"key":"10.1016\/j.bmc.2022.117131_b0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/bs.pbr.2019.10.007","article-title":"Novel approaches to counter protein aggregation pathology in Parkinson's disease","volume":"252","author":"Stott","year":"2020","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bmc.2022.117131_b0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bmc.2022.117131_b0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/277093a0","article-title":"Multiple receptors for dopamine","volume":"277","author":"Kebabian","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.117131_b0055","first-page":"501","article-title":"Gene cloning of human dopaminergic D3 receptor and identification of its chromosome","volume":"III 311","author":"Giros","year":"1990","journal-title":"C R Acad Sci"},{"key":"10.1016\/j.bmc.2022.117131_b0060","doi-asserted-by":"crossref","unstructured":"Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., and Schwartz, J. C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151, PMID 1975644.","DOI":"10.1038\/347146a0"},{"key":"10.1016\/j.bmc.2022.117131_b0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.117131_b0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/350614a0","article-title":"Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1","volume":"350","author":"Sunahara","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.117131_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0197-0186(93)90050-F","article-title":"New insights into dopamine receptors in the central nervous system","volume":"22","author":"Strange","year":"1993","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bmc.2022.117131_b0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.pa.33.040193.001433","article-title":"Molecular diversity of the dopamine receptors","volume":"33","author":"Civelli","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2022.117131_b0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0163-7258(99)00029-7","article-title":"Dopamine receptors\u2013physiological understanding to therapeutic intervention potential","volume":"84","author":"Emilien","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2022.117131_b0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/cr050263h","article-title":"Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders","volume":"107","author":"Zhang","year":"2007","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2022.117131_b0095","doi-asserted-by":"crossref","unstructured":"Foley, P., Gerlach, M., Double, K. L., and Riederer, P. (2004) Dopamine receptor agonists in the therapy of Parkinson\u2019s disease. Journal of Neural Transmission 111, 1375-1446, PMID.","DOI":"10.1007\/s00702-003-0059-x"},{"key":"10.1016\/j.bmc.2022.117131_b0100","doi-asserted-by":"crossref","unstructured":"Dutta PhD, A. K., and Le Md PhD, W. (2006) Existing dopaminergic therapies for Parkinsons disease. Expert Opinion on Therapeutic Patents 16, 1613-1625, PMID.","DOI":"10.1517\/13543776.16.12.1613"},{"key":"10.1016\/j.bmc.2022.117131_b0105","unstructured":"Birkmayer, W., and Hornykiewicz, O. (2001) The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 113, 851-854, PMID 11763859."},{"key":"10.1016\/j.bmc.2022.117131_b0110","unstructured":"Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C. W., Tanner, C., Marek, K., and Parkinson Study, G. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351, 2498-2508, PMID 15590952."},{"key":"10.1016\/j.bmc.2022.117131_b0115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2022.117131_b0120","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1212\/WNL.47.6_Suppl_3.184S","article-title":"Is levodopa toxic?","volume":"47","author":"Fahn","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bmc.2022.117131_b0125","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2174\/1381612003399581","article-title":"Dopamine agonists in the treatment of Parkinson s disease past, present and future","volume":"6","author":"Sit","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2022.117131_b0130","doi-asserted-by":"crossref","unstructured":"Schapira, A. H. (2009) Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 30, 41-47, PMID 19042040.","DOI":"10.1016\/j.tips.2008.10.005"},{"key":"10.1016\/j.bmc.2022.117131_b0135","doi-asserted-by":"crossref","unstructured":"Foley, P., Gerlach, M., Double, K. L., and Riederer, P. (2004) Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm (Vienna) 111, 1375-1446, PMID 15480844.","DOI":"10.1007\/s00702-003-0059-x"},{"key":"10.1016\/j.bmc.2022.117131_b0140","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/ml3002117","article-title":"Novel bivalent ligands for D2\/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency","volume":"3","author":"Gogoi","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2022.117131_b0145","doi-asserted-by":"crossref","unstructured":"Yedlapudi, D., Joshi, G. S., Luo, D., Todi, S. V., and Dutta, A. K. (2016) Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep 6, 38510, PMID 27917933.","DOI":"10.1038\/srep38510"},{"key":"10.1016\/j.bmc.2022.117131_b0150","article-title":"Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2\/D3 agonist D-520: Potential therapeutic application in Parkinson's disease with dementia","volume":"9, 19648, PMID 31873106","author":"Yedlapudi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2022.117131_b0155","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1074\/jbc.M403129200","article-title":"The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils","volume":"279","author":"Zhu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2022.117131_b0160","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cbic.201000604","article-title":"Baicalein inhibits formation of alpha-synuclein oligomers within living cells and prevents Abeta peptide fibrillation and oligomerisation","volume":"12","author":"Lu","year":"2011","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2022.117131_b0165","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm901618d","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.117131_b0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jneumeth.2010.01.031","article-title":"Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands. [3H]Spiperone binding to D2 and D3 dopamine receptors","volume":"188","author":"Zhen","year":"2010","journal-title":"J Neurosci Methods"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622005247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622005247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:20:33Z","timestamp":1760836833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622005247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"alternative-id":["S0968089622005247"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117131","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalent dopamine agonists with co-operative binding and functional activities at dopamine D2 receptors, modulate aggregation and toxicity of alpha synuclein protein","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117131"}}